GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Shares Outstanding (Basic Average)

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Shares Outstanding (Basic Average) : 0.00 Mil (As of Dec. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Eucrates Biomedical Acquisition's average basic shares outstanding for the quarter that ended in Dec. 2022 was 0.00 Mil.


Eucrates Biomedical Acquisition Shares Outstanding (Basic Average) Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Shares Outstanding (Basic Average) Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Shares Outstanding (Basic Average)
- - -

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eucrates Biomedical Acquisition Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Eucrates Biomedical Acquisition  (NAS:EUCRU) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Eucrates Biomedical Acquisition Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines